Location of Repository

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

By Jolanta Kupryjanczyk, Ewa Kraszewska, Izabela Ziolkowska-Seta, Radoslaw Madry, Agnieszka Timorek, Janina Markowska, Jerzy Stelmachow and Mariusz Bidzinski
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2268700
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2003). 3rd: Current status of taxane and platinumbased chemotherapy in ovarian cancer.
    2. (1981). A: Reporting results of cancer treatment. Cancer
    3. (1988). Announcement, FIGO stages revisions. Gynecol Oncol
    4. (2006). Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice. Gan To Kagaku Ryoho
    5. (1999). C: Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs.
    6. (2006). Cavazzana AO: P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res
    7. Cellular responses to DNA damage and cisplatin resistance.
    8. (1998). Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol
    9. (1999). Clinical significance of apoptosis-related factors
    10. (2002). Collaborative Ovarian Neoplasm (ICON) Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet
    11. (1997). Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res
    12. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    13. (1993). DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell
    14. (2007). DS: Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol
    15. (1995). DW: p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol
    16. (1993). DW: p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA
    17. (2003). Edited: Pathology and Genetics of Tumours of the Breast and Female Genital Organs World Health Organization Classification of Tumours,
    18. (2003). Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.
    19. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.
    20. (1997). G: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.
    21. (1999). Geard CR: Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation.
    22. (2006). Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Gene t
    23. (1995). Horwitz SB: Characterization of the taxol binding site on the microtubule. 2-(mAzidobenzoyl) taxol photolabels a peptide (amino acids 217–231) of beta-tubulin.
    24. (1979). Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature
    25. (1980). Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells.
    26. (1997). Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
    27. (1996). HR: The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer
    28. (2000). JM: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.
    29. (2005). Lichtman SM: Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist
    30. (1987). Lippard SJ: Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev
    31. (1996). Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med
    32. (2008). M: P53 status does not affectBMC Cancer
    33. (2001). MA: Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA
    34. (1999). Menick DR, Cabral F: A betatubulin leucine cluster involved in microtubule assembly and paclitaxel resistance.
    35. (1996). P i e r o t t i M A , L a v a r i n o C , C o r n a r o t t i
    36. (1997). p53 and apoptosis. Br Med Bull
    37. (1997). Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.
    38. (2005). Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma. Ai Zheng
    39. (2001). Press MF: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res
    40. (2006). Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett
    41. (2000). Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res
    42. (2000). S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
    43. (1999). Scambia G: p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
    44. (2005). Scambia G: The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res
    45. (2007). Shapira I, AApro M: International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literature.
    46. (1999). Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
    47. (2005). T: Cancer biology: sense out of missense. Nature
    48. (1998). Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.
    49. (2004). TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.
    50. (2001). Treatment of platinumresistant ovarian cancer. Expert Opin Pharmacother
    51. (1994). Trimble EL: Salvage chemotherapy for epithelial ovarian carcinoma.
    52. (2006). Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. Leukemia
    53. (2006). Why TP53 status does not associate with clinical endpoints in ovarian cancer: facts and hypotheses. Gynecol Oncol
    54. (2001). Zunino F: A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
    55. (2000). Zunino F: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.